CSMG Technologies Inc. (CTGI) Uncovers New Radiofrequency Vessel Sealing System
Wednesday December 10 2008
Company plans to launch its bipolar tissue management system in early 2009.
In recent years, electrosurgical technology has gained widespread use in nearly all fields of medicine. Electrosurgery is the application of a high-frequency electric current to human tissue as a means to remove lesions, staunch bleeding, or cut tissue. The first use of an electrosurgical generator in an operating room occurred on October 1, 1926. In modern times electrosurgery has expanded into surgical subspecialties with new procedures and new instrumentation developed by emerging companies. Over the last decade the technology has been expanded into specialized systems for the coaptation or sealing of vessels.
CSMG Technologies Inc. operates as a technology management company engaged in financing, owning, developing, patenting, managing, licensing and marketing technologies. Through its subsidiary, Live Tissue Connect Inc., CTGI provides live biological tissue bonding technology.
Live Tissue Connect Inc. (LTC) is a physician-focused company dedicated to the development of specialized third Generation bipolar devices. Consistent with this focus the company has established 6 divisions focusing on procedure specific product designs: General Surgery & Gynecology Medical Group Orthopaedic Tissue Sciences; Colorectal Connection Management; Pulmonary Sealing Sciences; Urologic Tissue Welding; Aesthetic Tissue Welding.
LTC introduces the BioFuse Tissue Sealing System, a proprietary third generation radiofrequency bipolar tissue management system that can seal and fuse most types of human tissues. The system consists of a generator - VAD.400 - and a series of bipolar forceps. To create seals the bipolar forceps are placed perpendicularly across the vessel or duct and the generator is energized. The system uses a new software algorithm and radiofrequency output that senses correct sealing and automatically stops current flow, minimizing tissue sticking and minimizing collateral tissue damage. The algorithm measures the important electrosurgical variables in real time and processes these variables to insure that the correct amount of energy is delivered. The system has demonstrated consistent and reliable seals in arteries with diameters up to and including 7 mm with little tissue sticking and minimal collateral thermal damage.
In late July, LTC received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its LTC VAD System in the USA. In addition, in October, the company has received approval of its fifth U.S. patent on a key divisional application for bonding/welding technology. LTC currently holds a total of approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Russia, China and other countries. In preparation for launching commercial product in early 2009, the company has begun building inventory for both LTC's electro surgery generator and hand instrument for duct and vessel sealing, and is in discussions with interested international medical device companies and distributors.
About CSMG Technologies
CSMG Technologies, Inc., formerly Consortium Service Management Group Inc., is a technology management company that finances, owns, develops, patents, manages, licenses and markets technologies. The Company’s technologies involve Live Tissue Bonding/Welding and Carbon dioxide (CO2) separation of landfill gas. CSMG is a Texas corporation with offices in Corpus Christi, Texas, Washington, D.C., Atlanta, Georgia, and Kiev, Ukraine.
News 
Market Data 
Discover 
